Crewe Advisors’s Bicycle Therapeutics BCYC Stock Holding History

Crewe Advisors’s Portfolio BCYC Stock Details BCYC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-83	Closed	-$1.77K	–	888
2023 Q1	$1.77K	Hold	83	–	–	﹤0.01%	728
2022 Q4	$2.46K	Hold	83	–	–	﹤0.01%	807
2022 Q3	$2K	Hold	83	–	–	﹤0.01%	1018
2022 Q2	$1K	Buy	+83	New	+$1.75K	﹤0.01%	1047

Other funds holding BCYC

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

JFG

Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TCM

Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Crewe Advisors's BCYC Position: Q2 2023 in Review

Crewe Advisors sold out of Bicycle Therapeutics (BCYC) in Q2 2023, closing a stake of 83 shares — an estimated $1.77K sold.

Crewe Advisors first reported a position in BCYC in Q2 2022 and held it in 4 quarters. The position peaked at $2.46K in Q4 2022. 85 funds tracked by Wall St. Rank hold BCYC as of Q2 2023.

Crewe Advisors reported no remaining Bicycle Therapeutics position as of Q2 2023 after selling out during the quarter.
Crewe Advisors sold 83 Bicycle Therapeutics shares in Q2 2023, an estimated $1.77K.
Crewe Advisors first reported a position in Bicycle Therapeutics in Q2 2022 and held it in 4 quarters.
Crewe Advisors's Bicycle Therapeutics position peaked at $2.46K in Q4 2022.
85 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q2 2023.

Based on Crewe Advisors's 13F filing for Q2 2023, filed 28 Jul 2023.